Insmed Incorporated (BST:IM8N)

Market Cap	24.77B
Revenue (ttm)	338.99M
Net Income (ttm)	-880.74M
Shares Out	n/a
EPS (ttm)	-4.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	13
Open	124.00
Previous Close	123.00
Day's Range	124.00 - 126.00
52-Week Range	55.00 - 126.00
Beta	n/a
RSI	90.26
Earnings Date	Oct 30, 2025

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 1,271
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: IM8N

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD